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SUMMARY
We report the cases of two patients who developed 
worsening behavioural and psychological 
symptoms of dementia (BPSD), coinciding 
with starting the factor Xa inhibitor direct 
oral anticoagulant medications apixaban and 
rivaroxaban, respectively. Both patients required 
detaining under the Mental Health Act. Their 
symptoms improved significantly, within 2 weeks, 
on switching to alternative anticoagulant therapies 
and they were both discharged from the acute 
psychiatric ward. Front- line staff should partake 
in postmarketing surveillance of medications, 
completing the Medicines and Healthcare products 
Regulatory Agency yellow cards for example (UK). 
There is increasing evidence for an aetiological 
role of cerebral mitochondrial dysfunction in 
neuropsychiatric disorders. Development of a 
rating scale of drugs that are potentially less toxic 
to cerebral mitochondria could inform national 
prescribing guidelines and enable safer treatments 
to be offered to older people, reducing the likely 
hood of them experiencing apparent BPSD.
BACKGROUND
Globally, the estimated proportion of the general 
population aged 60 and over with dementia 
is between 5% and 8% equating to around 
50 million people. There are nearly 10 million 
new cases every year.1 Ischaemic heart disease 
and stroke are the biggest cause of death world-
wide.2 Factor Xa inhibitor direct oral anticoag-
ulants (DOACs) have become widely prescribed 
over recent years in the UK, being included as 
drugs recommended by the National Institute 
for Health and Care Excellence as achieving 
anticoagulation in prevention of systemic 
emboli in patients in atrial fibrillation (AF) 
or with deep vein thrombosis. A significant 
proportion of the population with mild cogni-
tive impairment or dementia are, therefore, 
also treated with DOAC’s for these coexistent 
diagnoses. In our experience locally, reflecting 
changing practice throughout the developed 
world, many patients are being switched from 
warfarin to factor Xa inhibitor DOACs, which 
do not require close monitoring of blood levels. 
Despite no listed neuropsychiatric side effects 
in the British National Formulary (BNF) for 
these, we suspected that these two patients 
were experiencing iatrogenic worsening of their 
behavioural and psychological symptoms of 
dementia (BPSD). We hypothesise that similar 
factor Xa inhibitor side effects are experienced 
by many older people to a varying degree and 
wrongly attributed to BPSD.
CASE PRESENTATION 1
A woman in her early 80s was admitted to her 
local District General Hospital (DGH) following 
a fall. She was found to have a pulmonary embolus 
(PE) and to be in AF. She was commenced on 
apixaban. During this admission, staff raised 
concerns about her memory and on discharge, 
referred her to the local memory assessment 
service (MAS). Following initial MAS assessment 
approximately 3 weeks later, the patient was 
commenced on the antidepressant mirtazapine 
for low mood and poor sleep. However, after a 
further 3 weeks, she was brought to the liaison 
department at the DGH following physically 
assaulting police officers and paramedics. Her 
husband confirmed a deterioration in his wife’s 
memory over 6 months with her becoming repet-
itive in conversation and forgetting who some 
of the neighbours were. She had also started 
to accuse him of having an affair and steeling 
her money over these months. He denied this 
saying that they spent nearly all their time 
together. However, he indicated that there had 
been a noticeable worsening of her presentation 
following her hospital admission 6 weeks before 
with a PE, with her becoming physically aggres-
sive since, assaulting him on multiple occasions 
and calling the police frequently. He explained 
that he had had to lock himself in the bathroom 
that day for his own safety. At interview, the 
patient reported low mood and poor sleep since 
the alleged affair, saying that she had seen this 
person and found a slip in her husband’s pocket. 
Her mood was labile, alternating between irrita-
bility and tearfulness. She was noted to be repet-
itive in conversation with poor recall of recent 
events. Her insight was poor although she was 
aware of recent memory difficulties. She was 
assessed and admitted under section 2 of the 
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Mental Health Act (MHA) with a provisional diagnosis of 
delusional jealousy in the context of likely dementia.
INVESTIGATIONS
Physical examination was unremarkable. Medications 
included apixaban (5 mg two times per day), bisoprolol 
(2.5 mg two times per day), digoxin (125 μg one time per 
day) and glyceryl trinitrate spray as required. A dementia 
blood screen was normal. An MRI head scan showed minor 
generalised cerebral atrophy with a few foci within the 
supratentorial white matter reported as likely age related 
ischaemic phenomena. The patient scored 70/100 on the 
Addenbrooke’s cognitive examination, losing marks in the 
memory domain and suggestive of at least mild dementia.
MANAGEMENT
Mirtazapine was stopped as the patient’s agitation and 
aggression had only worsened. Subsequent trials of medi-
cation to manage this included intramuscular lorazepam 
(0.5–1.0 mg), required on several occasions; quetiapine 
(125 mg daily) combined with citalopram (20 mg daily), both 
subsequently stopped as not effective; replaced by aripip-
razole (15 mg daily), also ineffective and replaced by oral 
zuclopenthixol, (increased to 18 mg daily). After 2 weeks 
on this dose of zuclopenthixol and nearly 4 months on the 
acute psychiatric ward, although the patient was no longer 
expressing delusion ideas regarding, her husband having 
an affair her presentation had, if anything, worsened with 
regard to her agitation and aggression, throwing a chair, 
banging on the doors, hitting out at staff and asking for her 
mother. The decision was made to switch apixaban to dabig-
atran as an alternative DOAC. The rationale was that there 
had been no other obvious precipitating factors that might 
explain the relatively sudden and persistent deterioration in 
the patient’s mental state and the temporal relationship with 
starting apixaban. She became markedly more settled over 
the next 2 weeks, no longer banging on doors or wanting 
to leave. She acknowledged feeling more calm and relaxed. 
There were no longer concerns regarding her mood or sleep. 
This was in the absence of any other behavioural approach, 
medication or management changes.
OUTCOME AND FOLLOW-UP
The patient was discharged to a local care home, which 
would not have been considered possible prior to her 
switching anticoagulant medication and appearing far less 
agitated and aggressive. She was significantly more settled 
and her presentation was of mild dementia. Treatment with 
antipsychotic medication had been effective for her delu-
sional beliefs throughout her admission and she continued 
treatment with clopixol (18 mg daily). The management plan 
was to reduce this while monitoring her mental state for 
any re- emergence of BPSD agitation and aggression. After a 
month, both she and her husband were enquiring about the 
possibility of her returning home.
CASE PRESENTATION 2
The second case is of a man in his early 70s, described by his 
family as having some mild memory problems and confusion 
at times although managing his activities of daily living well 
enough. He did not think it severe enough to bother his 
general practitioner (GP). However, approximately a month 
after commencing rivaroxaban for AF, he became agitated 
and more confused. So much so that not only did he present 
to his GP, who referred him to our MAS, he was in turn 
referred to our older persons community mental health team, 
as his apparent BPSD had worsened rapidly. He had become 
physically threatening and aggressive towards his wife and 
daughters. He was assessed and admitted under the MHA 
and received a working diagnosis of advanced dementia. 
This led to trials of treatment with a variety of psychotropic 
medications. His apparent BPSD appeared to be treatment 
resistant and his presentation worsened.
At the time, in 2016, there were no side effects listed 
for rivaroxaban in the BNF which might have suggested 
the potential for worsening of mental state or cognition. 
However, in the absence of any other identifiable psychoso-
cial or pathophysiological causes or changes to medication, 
we switched rivaroxaban to warfarin. We saw a significant 
improvement in the patient’s presentation within 2 weeks. 
Importantly, further improvements were noted on gradu-
ally reducing and discontinuing the psychotropic medica-
tions that were being prescribed in an attempt to manage his 
change in behaviour. This patient had also became settled 
sufficiently to be discharged. He caught the bus home, a fact 
he was able to recount to us in clinic a month later when his 
clinical presentation was also of mild dementia.
DISCUSSION
Front- line healthcare staff in acute settings and the commu-
nity manage a heavy workload. It is all too easy to overlook 
potential neuropsychiatric drug side effects, especially if 
they are not clearly listed. They may be easily missed among 
older patients and wrongly attributed to dementia.
Rivaroxaban is structurally related to the antibiotic 
linezolid, which has been reported to cause mitochondrial 
toxicity.3 Premarketing in vitro studies concluded the risk 
of mitochondrial toxicity associated with this anticoagulant 
to be low.4 However, a more recent in vitro study, using rat 
kidney mitochondria, reported evidence of mitochondrial 
swelling and a collapse of the membrane potential following 
exposure to low doses of rivaroxaban.5 The effect of apix-
aban, which is structurally related to rivaroxaban, has yet to 
be investigated on mitochondrial function.6
Recent research supports not only an association between 
reduced cerebral mitochondrial function and neuropsychi-
atric symptoms and disorders, but also the aetiological role 
it may play.7
There is a need for a far greater awareness and under-
standing of the potential cerebral mitochondrial toxicity of 
drugs commonly prescribed to our older populations. These 
are numerous and include, for example, some of the drugs 
prescribed for diabetes (metformin) and raised cholesterol 
(statins) as well as many of those prescribed for neuropsy-
chiatric symptoms such as trazadone and sodium valproate.8
Asthenia (abnormal physical weakness or lack of energy) 
has more recently become listed as a common/very common 
side effect of rivaroxaban in the BNF. This is presumably 
as a result of the medicines and healthcare products regu-
latory agency (MHRA) yellow card reporting of suspected 
adverse reactions being submitted. This clinical symptom 
may be associated with mitochondrial toxicity.9 Interestingly, 
Karlsvik et al reported no increase in the level of fatigue 
after initiation of treatment with rivaroxaban.10
Further research could enable the compiling of a cerebral 
mitochondrial toxicity burden scale of drugs, similar to that 
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as already exists for anticholinergic burden on cognitive 
functioning.11 There are research techniques that can assess 
cerebral mitochondrial dysfunction using non- invasive brain 
scanning of lactate levels, which are considered to be a good 
correlate of mitochondrial function.12 Such a scale could 
inform clinical decision making, switching patients to drugs 
that are potentially less toxic to cerebral mitochondria, 
when appropriate.
We may then be able to significantly improve quality of 
life and reduce the burden and cost for patients, their carers, 
psychiatric services and the social care system by potentially 
avoiding psychiatric admission and placement in dementia 
care homes with fees, in the UK of between £34 000 (resi-
dential) and £47 000 (nursing) per annum.13
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Patient’s perspective
Something changed when I was in hospital after my fall, 
something wasn’t right. I feel calmer and much better now, 
ready to go back home with my husband.
Learning points
 ► Consider drug- induced neuropsychiatric symptoms in older 
patients with suspected behavioural and psychological 
symptoms of dementia (BPSD). Avoid assuming that their 
worsening presentation is necessarily secondary to cerebral 
emboli because they have a degree of vascular pathology on 
brain imaging and are in atrial fibrillation.
 ► Older patients are particularly prone to experiencing 
neuropsychiatric side effects of drugs that may not have 
been apparent during preclinical trials. Polypharmacy and 
associated drug interactions are also more common. All front- 
line staff should be encouraged to discuss with colleagues 
any medicine safety concerns, which can be particularly hard 
to unpick from BPSD, and to report these via the medicines 
and healthcare products regulatory agency yellow card 
system, for example.
 ► Neuropsychiatric symptoms and disorders are known to be 
associated with reduced cerebral mitochondrial function. 
There is an increasing body of research supporting that this 
relationship is aetiological. If so, any further drug- induced 
impairment of cerebral mitochondrial function could, 
therefore, be expected to precipitate or exacerbate such 
symptoms or disorders already present potentially.
 ► An increased awareness of which drugs are less toxic to 
cerebral mitochondria, with the development of a rating scale 
for example, could inform prescribing guidelines (National 
Institute for Health and Care Excellence) and safer treatments 
being offered to older people, reducing the likely hood of 
them experiencing apparent BPSD and requiring psychiatric 
detention.
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